Bredt David
Known title: Chief Scientific OfficerCIK: 0002022087
Associated companies
Transaction History
| RAPP | ▲ Buy | Option Exercise | 6,000 | $11K | 2/19/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 900 | $25K | 2/17/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 5,400 | $156K | 2/17/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 2,200 | $65K | 2/17/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,300 | $223K | 1/15/2026 | View on chart |
| RAPP | ▼ Sell | Open Market | 200 | $5K | 1/15/2026 | View on chart |
| RAPP | ▲ Buy | Grant | 18,000 | — | 12/31/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 6,567 | $197K | 12/31/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 7,704 | $231K | 12/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 796 | $24K | 12/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 3,156 | $78K | 11/17/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 5,344 | $136K | 11/17/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 7,418 | $191K | 10/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 1,082 | $28K | 10/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 5,098 | $122K | 9/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 3,402 | $84K | 9/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,300 | $124K | 8/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 200 | $3K | 8/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,500 | $119K | 7/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,500 | $94K | 6/16/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,500 | $81K | 5/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,500 | $81K | 4/15/2025 | View on chart |
| RAPP | ▼ Sell | Open Market | 8,500 | $92K | 3/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target
Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.